Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1629
This examiner grants 71% of resolved cases
Eric Tran is an examiner in Tech Center 1600, Art Unit 1629. The examiner has 113 resolved cases. The data shows an allowance rate of 70.8 percent and an interview lift of 23.3 percent. The median days to allowance for these cases is 1027.
The 23.3 percent interview lift is a metric that can be compared to the 70.8 percent base allowance rate. This indicates that conducting an interview is a method for increasing the likelihood of an allowance. The 1027 day median pendency is the timeframe applicants can expect when navigating the resolved cases handled by this examiner in Art Unit 1629. Practitioners can consider how these metrics influence the overall prosecution timeline.
With 113 resolved cases, the examiner's statistics provide a view of the prosecution landscape. Practitioners can use the 70.8 percent allowance rate to assess the probability of a grant. The 23.3 percent lift and the Tech Center 1600 environment are factors for prosecution strategy. These data points help in setting expectations for clients.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18703117 | COMPOSITION | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 18559184 | WDR5 INHIBITORS AND MODULATORS | Final Rejection | Vanderbilt University |
| 18566862 | Administration of a Compound to Individuals with Hepatic Impairment | Non-Final OA | Arena Pharmaceuticals, Inc. |
| 18416336 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | Non-Final OA | Intervet Inc. |
| 18744161 | COMPOSITIONS AND METHODS OF TREATING INVASIVE PATHOGENS | Non-Final OA | Duke University |
| 18508831 | R-KETAMINE AND DERIVATIVE THEREOF AS PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEURODEGENERATION DISEASE OR RECOGNITION FUNCTIONAL DISORDER | Final Rejection | National University Corporation Chiba University |
| 18780727 | METHODS OF TREATING HEART FAILURE WITH HIBERNATING MYOCARDIUM USING MODIFIED FORMS OF TRIMETAZIDINE | Non-Final OA | IMBRIA PHARMACEUTICALS, INC. |
| 18743985 | C-7 FUNCTIONALIZED ARTEMISININ DERIVATIVES FOR THE TREATMENT OF MALARIA | Non-Final OA | University of the Incarnate Word |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy